Cullinan Therapeutics
Cambridge · Founded 2017
About Cullinan Therapeutics
Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.
Company Facts
- Founded: 2017
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Total funding: $669.7M
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2024)
- Ticker: nasdaq:CGEM
- Website: cullinanoncology.com
- Phone: +1 617 410 4650
Industries & Categories
Biopharma, Biotechnology, Medical Device, Oncology
Social Profiles
Canonical: https://fsome.com/organization/cullinan-therapeutics-84082 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.